Literature DB >> 20127691

Honokiol inhibits HepG2 migration via down-regulation of IQGAP1 expression discovered by a quantitative pharmaceutical proteomic analysis.

Shufang Liang1, Afu Fu, Qiang Zhang, Minghai Tang, Jin Zhou, Yuquan Wei, Lijuan Chen.   

Abstract

Honokiol (HNK), a natural small molecular product, inhibited proliferation of HepG2 cells and exhibited anti-tumor activity in nude mice. In this article, we applied a novel sensitive stable isotope labeling with amino acids in cell culture-based quantitative proteomic method and a model of nude mice to investigate the correlation between HNK and the hotspot migration molecule Ras GTPase-activating-like protein (IQGAP1). The quantitative proteomic analysis showed that IQGAP1 was 0.53-fold down-regulated under 10 microg/mL HNK exposure for 24 h on HepG2 cells. Migration ability of HepG2 cells under HNK treatment was correlated with its expression level of IQGAP1. In addition, the biochemical validation on HepG2 cells and the tumor xenograft model further demonstrated that HNK decreased the expression level of IQGAP1 and its upstream proteins Cdc42/Rac1. These data supported that HNK can modulate cell adhesion and cell migration by acting on Cdc42/Rac1 signaling via IQGAP1 interactions with its upstream Cdc42/Rac1 proteins, which is a new molecular mechanism of HNK to exert its anti-tumor activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127691     DOI: 10.1002/pmic.200900649

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  11 in total

1.  YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.

Authors:  Youzhi Xu; Hongjun Lin; Nana Meng; Wenjie Lu; Guobo Li; Yuanyuan Han; Xiaoyun Dai; Yong Xia; Xiangrong Song; Shengyong Yang; Yuquan Wei; Luoting Yu; Yinglan Zhao
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

2.  Comparisons of three polyethyleneimine-derived nanoparticles as a gene therapy delivery system for renal cell carcinoma.

Authors:  Zhizhong Xu; Guobo Shen; Xiangying Xia; Xinyu Zhao; Peng Zhang; Huanhuan Wu; Qingfa Guo; Zhiyong Qian; Yuquan Wei; Shufang Liang
Journal:  J Transl Med       Date:  2011-04-23       Impact factor: 5.531

3.  Piwil2 suppresses p53 by inducing phosphorylation of signal transducer and activator of transcription 3 in tumor cells.

Authors:  Yilu Lu; Kun Zhang; Chao Li; Youlin Yao; Dachang Tao; Yunqiang Liu; Sizong Zhang; Yongxin Ma
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

4.  A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities.

Authors:  Youzhi Xu; Wenjie Lu; Peng Yang; Wen Peng; Chunting Wang; Manli Li; Yan Li; Guobo Li; Nana Meng; Hongjun Lin; Lixin Kan; Siying Wang; Shengyong Yang; Luoting Yu; YingLan Zhao
Journal:  BMC Cancer       Date:  2015-07-18       Impact factor: 4.430

5.  Antineoplastic Effects of Honokiol on Melanoma.

Authors:  Ruth Guillermo-Lagae; Sreevidya Santha; Milton Thomas; Emily Zoelle; Jonathan Stevens; Radhey S Kaushik; Chandradhar Dwivedi
Journal:  Biomed Res Int       Date:  2017-01-17       Impact factor: 3.411

6.  Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells.

Authors:  Yujuan Chen; Xiaoyun Wang; Chuan Cao; Xiaodong Wang; Shufang Liang; Cheng Peng; Leilei Fu; Gu He
Journal:  Oncotarget       Date:  2017-10-26

7.  SILAC-based quantitative MS approach for real-time recording protein-mediated cell-cell interactions.

Authors:  Xixi Wang; Yu He; Yang Ye; Xinyu Zhao; Shi Deng; Gu He; Hongxia Zhu; Ningzhi Xu; Shufang Liang
Journal:  Sci Rep       Date:  2018-05-31       Impact factor: 4.379

Review 8.  Proteomic Analysis of Anticancer TCMs Targeted at Mitochondria.

Authors:  Yang Wang; Ru-Yuan Yu; Qing-Yu He
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-19       Impact factor: 2.629

Review 9.  Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma.

Authors:  Hui-Tzu Hsu; Chin-Wen Chi
Journal:  J Hepatocell Carcinoma       Date:  2014-08-26

10.  STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways.

Authors:  Bing Chen; Xiao Zeng; Yu He; Xixi Wang; Ziwei Liang; Jingjing Liu; Peng Zhang; Hongxia Zhu; Ningzhi Xu; Shufang Liang
Journal:  Oncotarget       Date:  2016-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.